NEUROLOGY 1998;50:1222-1230
© 1998 American Academy of Neurology
Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease
John C. Morris, MD,
Pamela A. Cyrus, MD,
John Orazem, PhD,
Janice Mas, BS,
Florian Bieber, MD,
Bianca B. Ruzicka, PhD and
Barbara Gulanski, MD
From the Washington University in St. Louis (Dr. Morris), School of Medicine, St. Louis, MO; and Bayer Corporation (Drs. Cyrus, Orazem, Bieber, Ruzicka, and Gulanski, and J. Mas), Pharmaceutical Division, West Haven, CT.
Address correspondence and reprint requests to Dr. John C. Morris, Department of Neurology, Washington University School of Medicine, Campus Box 8111, 660 South Euclid Ave., St. Louis, MO 63110-1093.
Objective: To evaluate the efficacy and safety of metrifonate, an acetylcholinesterase inhibitor, in patients clinically diagnosed with probable Alzheimer's disease(AD) of mild to moderate severity.
Methods: A prospective, 36-week, multicenter, double-blind, randomized, parallel group study of metrifonate in probable AD patients, including a 2-week screening period, a 26-week double-blind treatment period, and a follow-up visit at 8 weeks post-treatment. A total of 24 ambulatory clinics in the United States in a variety of settings, including contract research organizations, public health facilities, and universities. Patients met diagnostic criteria for probable AD as defined by the work group of the National Institute for Neurological and Communicative Diseases and Stroke and the Alzheimer's Disease and Related Disorders Association. Patients had Mini-Mental State Examination (MMSE) scores of 10 to 26 and Ischemic Scores(Rosen Modification) of <4. A total of 408 patients were enrolled. Percentages of patients completing double-blind treatment were 88% and 79% in the placebo and metrifonate groups, respectively. Rates of discontinuation due to adverse events were 4% in the placebo group and 12% in the metrifonate group. Placebo or metrifonate was administered once daily. Metrifonate-treated patients received a loading dose of 100 to 180 mg based on weight (2.0 mg/kg) for 2 weeks, followed by a maintenance dose of 30 to 60 mg based on weight(0.65 mg/kg) for 24 weeks. Primary efficacy variables were the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) and the Clinician's Interview-Based Impression of Change with Caregiver Input (CIBIC-plus). Secondary efficacy variables included the Neuropsychiatric Inventory (NPI), the Disability Assessment in Dementia, the Global Deterioration Scale (GDS), the ADAS-Noncognitive subscale (ADAS-Noncog), the MMSE, and the Clinician's Interview-Based Impression of Severity with Caregiver Input (CIBIS-plus). Outcome measures reflected changes from baseline at week 26 for all variables. Safety was assessed with incidences of premature termination, treatment-emergent events and mortality, and routine safety evaluations.
Results: After 26 weeks of metrifonate therapy, a 2.86-point treatment difference(p = 0.0001) was observed in the ADAS-Cog scores of the intent-to-treat AD patients. The treatment difference in the mean CIBIC-plus score at this time was 0.28 points (p = 0.0071). At week 26, treatment differences also were observed in the mean NPI total score(p = 0.0161). Analysis of the remaining secondary efficacy variables showed treatment differences that favored metrifonate but did not reach statistical significance. Metrifonate adverse events were predominantly mild in intensity. No hepatotoxicity was observed.
Conclusions: Metrifonate was safe and well-tolerated. It enhanced not only the cognitive and global function, but also the behavioral function of patients diagnosed with mild to moderate AD. Therefore, metrifonate appears to be useful in the symptomatic treatment of AD.
Received August 20, 1997. Accepted in final form February 16, 1998.
This article has been cited by other articles:
|
|
|
|
 
C. C. Kaczorowski and J. F. Disterhoft
Memory deficits are associated with impaired ability to modulate neuronal excitability in middle-aged mice
Learn. Mem.,
May 23, 2009;
16(6):
362 - 366.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. S. Chappell, C. Gonzales, J. Williams, M. M. Witte, R. C. Mohs, and R. Sperling
AMPA potentiator treatment of cognitive deficits in Alzheimer disease
Neurology,
March 27, 2007;
68(13):
1008 - 1012.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Rozzini, B. V. Chilovi, E. Bertoletti, M. Conti, I. Delrio, M. Trabucchi, and A. Padovani
Cognitive and Psychopathologic Response to Rivastigmine in Dementia With Lewy Bodies Compared to Alzheimer's Disease: A Case Control Study
American Journal of Alzheimer's Disease and Other Dementias,
February 1, 2007;
22(1):
42 - 47.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. R. Peters, K. Rockwood, S. E. Black, R. Bouchard, S. Gauthier, D. Hogan, A. Kertesz, I. Loy-English, B. L. Beattie, A. D. Sadovnick, et al.
Characterizing neuropsychiatric symptoms in subjects referred to dementia clinics
Neurology,
February 28, 2006;
66(4):
523 - 528.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. D. Rankin and R. D. Layne
The Use of Olanzapine in the Treatment of Negative Symptoms in Alzheimer's Disease
J Neuropsychiatry Clin Neurosci,
August 1, 2005;
17(3):
423 - 424.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K Rockwood
Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease
J. Neurol. Neurosurg. Psychiatry,
May 1, 2004;
75(5):
677 - 685.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. H.S. Silverman
Brain 18F-FDG PET in the Diagnosis of Neurodegenerative Dementias: Comparison with Perfusion SPECT and with Clinical Evaluations Lacking Nuclear Imaging
J. Nucl. Med.,
April 1, 2004;
45(4):
594 - 607.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Cummings, L. Schneider, P. N. Tariot, P. R. Kershaw, and W. Yuan
Reduction of Behavioral Disturbances and Caregiver Distress by Galantamine in Patients With Alzheimer's Disease
Am J Psychiatry,
March 1, 2004;
161(3):
532 - 538.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. M. Bassiony and C. G. Lyketsos
Delusions and Hallucinations in Alzheimer's Disease: Review of the Brain Decade
Psychosomatics,
October 1, 2003;
44(5):
388 - 401.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N.-H. Trinh, J. Hoblyn, S. Mohanty, and K. Yaffe
Efficacy of Cholinesterase Inhibitors in the Treatment of Neuropsychiatric Symptoms and Functional Impairment in Alzheimer Disease: A Meta-analysis
JAMA,
January 8, 2003;
289(2):
210 - 216.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. E. Tractenberg, M. F. Weiner, M. B. Patterson, A. Gamst, and L. J. Thai
Emergent Psychopathology in Alzheimer's Disease Patients Over 12 Months Associated with Functional, Not Cognitive, Changes
J Geriatr Psychiatry Neurol,
June 1, 2002;
15(2):
110 - 117.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. C. Chappell and H. Cohen
Frontiers in Neuropharmacotherapy Part I: Alzheimer's Disease and Epilepsy
Journal of Pharmacy Practice,
June 1, 2002;
15(3):
195 - 220.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. H.S. Silverman, S. S. Gambhir, H.-W. C. Huang, J. Schwimmer, S. Kim, G. W. Small, J. Chodosh, J. Czernin, and M. E. Phelps
Evaluating Early Dementia With and Without Assessment of Regional Cerebral Metabolism by PET: A Comparison of Predicted Costs and Benefits
J. Nucl. Med.,
February 1, 2002;
43(2):
253 - 266.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K Rockwood, J Mintzer, L Truyen, T Wessel, and D Wilkinson
Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial
J. Neurol. Neurosurg. Psychiatry,
November 1, 2001;
71(5):
589 - 595.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Cummings, A. Nadel, D. Masterman, and P. A. Cyrus
Efficacy of Metrifonate in Improving the Psychiatric and Behavioral Disturbances of Patients with Alzheimer's Disease
J Geriatr Psychiatry Neurol,
June 1, 2001;
14(2):
101 - 108.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. R. Daffner, D.M. Rentz, L. F.M. Scinto, R. Faust, A. E. Budson, and P. J. Holcomb
Pathophysiology underlying diminished attention to novel events in patients with early AD
Neurology,
May 22, 2001;
56(10):
1377 - 1383.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. Doody, J.C. Stevens, C. Beck, R.M. Dubinsky, J.A. Kaye, L. Gwyther, R.C. Mohs, L.J. Thal, P.J. Whitehouse, S.T. DeKosky, et al.
Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology
Neurology,
May 8, 2001;
56(9):
1154 - 1166.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Power, M. M. Oh, and J. F. Disterhoft
Metrifonate Decreases sIAHP in CA1 Pyramidal Neurons In Vitro
J Neurophysiol,
January 1, 2001;
85(1):
319 - 322.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Demers, M. Oremus, A. Perrault, and C. Wolfson
Review of Outcome Measurement Instruments in Alzheimer's Disease Drug Trials: Introduction
J Geriatr Psychiatry Neurol,
December 1, 2000;
13(4):
161 - 168.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Perrault, M. Oremus, L. Demers, S. Vida, and C. Wolfson
Review of Outcome Measurement Instruments in Alzheimer's Disease Drug Trials: Psychometric Properties of Behavior and Mood Scales
J Geriatr Psychiatry Neurol,
December 1, 2000;
13(4):
181 - 196.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. A. Raskind, E. R. Peskind, T. Wessel, and W. Yuan
Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension
Neurology,
June 27, 2000;
54(12):
2261 - 2268.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. N. Tariot, P. R. Solomon, J. C. Morris, P. Kershaw, S. Lilienfeld, and C. Ding
A 5-month, randomized, placebo-controlled trial of galantamine in AD
Neurology,
June 27, 2000;
54(12):
2269 - 2276.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Paulsen, D. P. Salmon, L. J. Thal, R. Romero, C. Weisstein-Jenkins, D. Galasko, C. R. Hofstetter, R. Thomas, I. Grant, and D. V. Jeste
Incidence of and risk factors for hallucinations and delusions in patients with probable AD
Neurology,
May 23, 2000;
54(10):
1965 - 1971.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Gelinas, S. Gauthier, and PamelaA. Cyrus
Metrifonate Enhances the Ability of Alzheimer's Disease Patients to Initiate, Organize, and Execute Instrumental and Basic Activities of Daily Living
J Geriatr Psychiatry Neurol,
April 1, 2000;
13(1):
9 - 16.
[Abstract]
[PDF]
|
|
|
|
|
|
|
N. C. Fox, S. Cousens, R. Scahill, R. J. Harvey, and M. N. Rossor
Using Serial Registered Brain Magnetic Resonance Imaging to Measure Disease Progression in Alzheimer Disease: Power Calculations and Estimates of Sample Size to Detect Treatment Effects
Arch Neurol,
March 1, 2000;
57(3):
339 - 344.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. H. van Dyck, P. Newhouse, W. E. Falk, J. A. Mattes, and for the Physostigmine Study Group
Extended-Release Physostigmine in Alzheimer Disease: A Multicenter, Double-blind, 12-Week Study With Dose Enrichment
Arch Gen Psychiatry,
February 1, 2000;
57(2):
157 - 164.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. J. Thal, M. Forrest, H. Loft, and H. Mengel
Lu 25-109, a muscarinic agonist, fails to improve cognition in Alzheimer's disease
Neurology,
January 25, 2000;
54(2):
421 - 421.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Farlow, P. A. Cyrus, A. Nadel, D. K. Lahiri, A. Brashear, and B. Gulanski
Metrifonate treatment of AD: Influence of APOE genotype
Neurology,
December 1, 1999;
53(9):
2010 - 2010.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Mayeux and M. Sano
Treatment of Alzheimer's Disease
N. Engl. J. Med.,
November 25, 1999;
341(22):
1670 - 1679.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Mega, D. M. Masterman, S. M. O'Connor, T. R. Barclay, and J. L. Cummings
The Spectrum of Behavioral Responses to Cholinesterase Inhibitor Therapy in Alzheimer Disease
Arch Neurol,
November 1, 1999;
56(11):
1388 - 1393.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T BABIC;, P. T FRANCIS, A. M PALMER, M. SNAPE, and G. K WILCOCK
The cholinergic hypothesis of Alzheimer's disease: a review of progress
J. Neurol. Neurosurg. Psychiatry,
October 1, 1999;
67(4):
558 - 558.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. M. McLendon and P. M. Doraiswamy
Defining Meaningful Change in Alzheimer's Disease Trials: The Donepezil Experience
J Geriatr Psychiatry Neurol,
April 1, 1999;
12(1):
39 - 48.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. J. Thal, J. M. Ferguson, J. Mintzer, A. Raskin, and S. D. Targum
A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease
Neurology,
April 1, 1999;
52(6):
1146 - 1146.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. M. Oh, J. M. Power, L. T. Thompson, P. L. Moriearty, and J. F. Disterhoft
Metrifonate Increases Neuronal Excitability in CA1 Pyramidal Neurons from Both Young and Aging Rabbit Hippocampus
J. Neurosci.,
March 1, 1999;
19(5):
1814 - 1823.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. P. Imbimbo, P. Martelli, W. M. Troetel, F. Lucchelli, U. Lucca, and L. J. Thal
Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease
Neurology,
March 1, 1999;
52(4):
700 - 700.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
P. T Francis, A. M Palmer, M. Snape, and G. K Wilcock
The cholinergic hypothesis of Alzheimer's disease: a review of progress
J. Neurol. Neurosurg. Psychiatry,
February 1, 1999;
66(2):
137 - 147.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
T. A. Sandson and D. Knopman
Metrifonate for Alzheimer's disease: Is the next cholinesterase inhibitor better?
Neurology,
February 1, 1999;
52(3):
673 - 673.
[Full Text]
|
|
|
|
|
|
|
R. Luckmann
Metrifonate was effective in mild to moderate Alzheimer's disease
Evid. Based Ment. Health,
November 1, 1998;
1(4):
116 - 116.
[Full Text]
|
|
|
|
|
|
|
D. Knopman, J. Kahn, and S. Miles
Clinical Research Designs for Emerging Treatments for Alzheimer Disease: Moving Beyond Placebo-Controlled Trials
Arch Neurol,
November 1, 1998;
55(11):
1425 - 1429.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Rao and C. G. Lyketsos
Delusions in Alzheimer's Disease: A Review
J Neuropsychiatry Clin Neurosci,
November 1, 1998;
10(4):
373 - 382.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
Metrifonate Improves Cognitive Function in AD
Journal Watch Psychiatry,
August 1, 1998;
1998(801):
10 - 10.
[Full Text]
|
|
|
|
|
|
|
Another Cholinesterase Inhibitor for Alzheimer's Disease
Journal Watch (General),
June 16, 1998;
1998(616):
4 - 4.
[Full Text]
|
|
|
|
